Location: East Midlands
Location: North West England
Location: South East Coast
Speciality: Pharmacy Technician
A new recommendation has been issued by the National Institute of Care and Health Excellence (NICE) for the treatment of type II diabetes.
Adults in the UK will now be offered Steglatro (ertugliflozin) on the NHS as a monotherapy or as part of a dual therapy programme alongside metformin.
The sodium-glucose cotransporter-2 (SGLT-2) inhibitor has a 20 per cent lower acquisition cost than other SGLT-2 inhibitors, making it an attractive option for many people with the disorder.
It works out at a once daily dose costing just £29.40 for 28 days' of treatment. In trials, scientists recorded noticeable changes in HbA1c from baseline to the 26th week.
Louise Houson, managing director of MSD UK & Ireland, which makes the drug, told Pharma Times: “The decision by NICE shows MSD’s commitment to meeting the needs of a growing population of people with type II diabetes.
“We recognise the financial burden that an increasing number of people living with chronic conditions, such as type II diabetes, puts on resources and we continue to work closely with NICE and the NHS to increase access to new treatments which could improve the standard of care, while trying to lessen the economic pressures often associated with them.”
At present it’s estimated that 3.7 million people in the UK are living with diabetes, which equates to around seven per cent of the population.
This figure represents a doubling of the number diagnosed in the last 20 years, with inactivity and obesity among its causes.
It is thought that on top of those who have been diagnosed with type II diabetes, there are around 12.3 million people at an increased risk of developing the condition.
Written by James Puckle
Search Mediplacements for the latest pharmacy jobs.
According to the National Migraine Centre, one in seven people around the globe are affected by migraines,...
The NHS has made a new offer to a drug company to provide medicine for potentially thousands of cystic fibrosis...
Spinal muscular atrophy (SMA) is a rare genetic disease that up until now has had no treatment for the underlying...
Primary progressive multiple sclerosis (PPMS) is a rare form of MS that affects less than 15 per cent of people...